Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | Director | June 18, 2026 | June 23, 2026 |
| Twist Bioscience CorpTWST · Entity 3619 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 24,852 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 24,852 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,248 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 4,248 · Balance 4,248 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Twist Bioscience Corp
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 562,760 |
Ending reported balance
After 2026-10-05 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-10-05 · Sale · Disposed 1,840 · Balance 565,468 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 2 · 2026-10-05 · Sale · Disposed 481 · Balance 564,987 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-10-05 · Sale · Disposed 1,017 · Balance 563,970 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 4 · 2026-10-05 · Sale · Disposed 432 · Balance 563,538 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 5 · 2026-10-05 · Sale · Disposed 290 · Balance 563,248 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 6 · 2026-10-05 · Sale · Disposed 297 · Balance 562,951 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 7 · 2026-10-05 · Sale · Disposed 146 · Balance 562,805 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 8 · 2026-10-05 · Sale · Disposed 45 · Balance 562,760 F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026. F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.33 · Expires 2029-10-23 | Direct | 131,290 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 131,290 F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.85 · Expires 2030-08-31 | Direct | 64,950 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 64,950 F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
F2: Represents the weighted average sales price per share. The shares sold at prices ranging from $200 to $200.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: Represents the weighted average sales price per share. The shares sold at prices ranging from $201 to $201.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4: Represents the weighted average sales price per share. The shares sold at prices ranging from $202 to $202.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F5: Represents the weighted average sales price per share. The shares sold at prices ranging from $203.29 to $203.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6: Represents the weighted average sales price per share. The shares sold at prices ranging from $204.33 to $205.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F7: Represents the weighted average sales price per share. The shares sold at prices ranging from $205.37 to $206.34 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F8: Represents the weighted average sales price per share. The shares sold at prices ranging from $206.38 to $207.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F9: Represents the weighted average sales price per share. The shares sold at prices ranging from $207.38 to $207.8 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F10: 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F11: Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 113,318 | $26.66 | $3,021,057.88 |
DisclosureSEC source: 0001214659-26-009994 · marketforms-73750.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 932,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,101 | $85.32 | $435,223.44 |
DisclosureSEC source: 0001214659-26-009655 · marketforms-73659.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818,938 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:41 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 18,880 | $95.00 | $1,793,600.00 |
DisclosureSEC source: 0001214659-26-007800 · marketforms-73475.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 824,039 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,688 | $87.32 | $147,400.21 |
DisclosureSEC source: 0001214659-26-007692 · marketforms-73447.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 842,919 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:27 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 3,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001753655-26-000002 · form4-06232026_080626.xml · derivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 3,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F3 · derivative.expiration_date: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:27 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 4,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001753655-26-000002 · form4-06232026_080626.xml · derivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,248 Underlying: Class A Common Stock · 4,248 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. F2 · derivative.expiration_date: The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:27 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 3,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001753655-26-000002 · form4-06232026_080626.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,265 | $69.84 | $158,197.11 |
DisclosureSEC source: 0001214659-26-007316 · marketforms-73369.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 844,607 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,470 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-26-006967 · marketforms-73308.xml · derivative · entry 10 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,439 Underlying: Common Stock · 16,470 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,465 | $68.61 | $443,590.16 |
DisclosureSEC source: 0001214659-26-006967 · marketforms-73308.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 846,872 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $68.240 to $69.190 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,623 | $67.95 | $517,988.95 |
DisclosureSEC source: 0001214659-26-006967 · marketforms-73308.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 853,337 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $67.240 to $68.2375 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 900 | $66.85 | $60,162.93 |
DisclosureSEC source: 0001214659-26-006967 · marketforms-73308.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 860,960 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $66.240 to $67.210 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,482 | $65.33 | $96,812.54 |
DisclosureSEC source: 0001214659-26-006967 · marketforms-73308.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 861,860 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.820 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 16,470 | $8.82 | $145,265.40 |
DisclosureSEC source: 0001214659-26-006967 · marketforms-73308.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 863,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,017 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-26-006835 · marketforms-73281.xml · derivative · entry 11 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,909 Underlying: Common Stock · 25,017 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,265 | $66.28 | $83,845.84 |
DisclosureSEC source: 0001214659-26-006835 · marketforms-73281.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 846,872 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $66.09 to $66.72 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 23,752 | $65.24 | $1,549,561.48 |
DisclosureSEC source: 0001214659-26-006835 · marketforms-73281.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 848,137 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 25,017 | $8.82 | $220,649.94 |
DisclosureSEC source: 0001214659-26-006835 · marketforms-73281.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 871,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,282 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-26-006835 · marketforms-73281.xml · derivative · entry 10 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,926 Underlying: Common Stock · 24,282 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 24,282 | $65.08 | $1,580,245.85 |
DisclosureSEC source: 0001214659-26-006835 · marketforms-73281.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 846,872 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.505 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 24,282 | $8.82 | $214,167.24 |
DisclosureSEC source: 0001214659-26-006835 · marketforms-73281.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 871,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 6,888 | $53.26 | $366,834.22 |
DisclosureSEC source: 0001214659-26-006713 · marketforms-73245.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,872 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,127 | $57.15 | $293,001.90 |
DisclosureSEC source: 0001214659-26-005675 · marketforms-73057.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 853,760 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,061 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-26-005005 · marketforms-72977.xml · derivative · entry 11 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,208 Underlying: Common Stock · 8,061 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 151 | $66.00 | $9,966.00 |
DisclosureSEC source: 0001214659-26-005005 · marketforms-72977.xml · nonDerivative · entry 5 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 858,887 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $66.00 to $66.01 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,910 | $65.28 | $516,325.25 |
DisclosureSEC source: 0001214659-26-005005 · marketforms-72977.xml · nonDerivative · entry 4 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 859,038 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.87 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 22, 2026 Filed Apr 23, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 8,061 | $8.82 | $71,098.02 |
DisclosureSEC source: 0001214659-26-005005 · marketforms-72977.xml · nonDerivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 866,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,610 | $0.00 Strike: $8.82 | $0.00 |
DisclosureSEC source: 0001214659-26-005005 · marketforms-72977.xml · derivative · entry 10 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,269 Underlying: Common Stock · 1,610 shares Expires 2027-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,610 | $65.01 | $104,666.10 |
DisclosureSEC source: 0001214659-26-005005 · marketforms-72977.xml · nonDerivative · entry 2 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 858,887 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.06 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 21, 2026 Filed Apr 23, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | Exercise / conversionCommon Stock | 1,610 | $8.82 | $14,200.20 |
DisclosureSEC source: 0001214659-26-005005 · marketforms-72977.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 860,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,742 | $43.79 | $76,275.91 |
DisclosureSEC source: 0001214659-26-003721 · marketforms-72713.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 858,887 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,423 | $46.43 | $112,490.20 |
DisclosureSEC source: 0001214659-26-003063 · marketforms-72430.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 860,629 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 7,205 | $46.71 | $336,544.11 |
DisclosureSEC source: 0001214659-26-002441 · marketforms-72311.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,052 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · balance_after: Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,001 | $46.58 | $232,926.58 |
DisclosureSEC source: 0001214659-26-001240 · marketforms-72017.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 869,312 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,605 | $34.56 | $55,462.38 |
DisclosureSEC source: 0001214659-25-018401 · marketforms-71693.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 874,313 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,255 | $32.88 | $74,139.89 |
DisclosureSEC source: 0001214659-25-017849 · marketforms-71490.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 875,918 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,663 | $26.50 | $70,578.82 |
DisclosureSEC source: 0001214659-25-017218 · marketforms-71346.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 878,173 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 146,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-017002 · marketforms-71303.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 880,836 F1 · shares: Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 4,887 | $32.08 | $156,772.03 |
DisclosureSEC source: 0001214659-25-015971 · marketforms-71203.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 733,922 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 21:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 31,379 | $31.44 | $986,690.69 |
DisclosureSEC source: 0001214659-25-015764 · marketforms-71187.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 738,809 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | GrantCommon Stock | 168,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-015584 · marketforms-71171.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 770,188 F1 · shares: Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 31,348 | $32.19 | $1,008,998.08 |
DisclosureSEC source: 0001214659-25-014776 · marketforms-70990.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 601,212 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 476 | $29.16 | $13,880.64 |
DisclosureSEC source: 0001214659-25-014665 · marketforms-70941.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 632,560 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:07 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,704 | $27.56 | $46,962.24 |
DisclosureSEC source: 0001214659-25-014121 · marketforms-70835.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,036 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 13:12 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,265 | $25.76 | $58,346.40 |
DisclosureSEC source: 0001214659-25-013566 · marketforms-70711.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,740 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 2,716 | $25.96 | $70,518.22 |
DisclosureSEC source: 0001214659-25-012709 · marketforms-70341.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 637,005 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 5,585 | $28.36 | $158,412.94 |
DisclosureSEC source: 0001214659-25-011610 · marketforms-70155.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639,721 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 476 | $36.19 | $17,227.87 |
DisclosureSEC source: 0001214659-25-010084 · marketforms-70057.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,306 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:05 UTC | Twist Bioscience Corp TWST · Entity 3619 | SaleCommon Stock | 1,678 | $35.76 | $59,996.89 |
DisclosureSEC source: 0001214659-25-009549 · marketforms-69975.xml · nonDerivative · entry 1 Leproust Emily M. · CIK 0001753655 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645,782 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:45 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 12,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017989 · form4-06232025_090651.xml · derivative · entry 3 Leproust Emily M. · CIK 0001753655 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F2 · derivative.expiration_date: The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.